There is an unspoken message embedded in this announcement: we know better than you (our Jewish community) what kind of truth ...
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of ...
Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...
In its second major partnership with a big pharma group, UK-based AI and multi-omics company Relation Therapeutics has agreed to seek out targets for allergic diseases on behalf of Novartis. The ...
Novartis has tapped up an artificial-intelligence-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions. What caught the Swiss pharma’s eye ...
PROF. SHAND'S interesting and original book is, as he says in the preface, the outcome of three insistent wishes: first, to clean up the “jungle of rock names;” second, to make the results and ...
Introduction Atrial fibrillation (AF) is the leading cause of cardioembolic stroke and is associated with increased stroke severity and fatality. Early identification of AF is essential for adequate ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Introduction Self-harm and suicidal thoughts and behaviours are a significant public health concern. While individual risk factors have been widely studied, the role of social determinants in shaping ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Novartis AG (NVS) to pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat allergic diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback